Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients

Kidney International

Volumn 66, Issue 2, 2004, Pages 832-840

  Frank, Helga ^a   Heusser, Karsten ^b   Höffken, Bernd ^b   Huber, Peter ^b   Schmieder, Roland E ^b   Schobel, Hans P ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

Anemia; Erythropoietin; Renal insufficiency; Sympathetic nerve activity

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOREARM; GEOMETRY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONGITUDINAL STUDY; LOWER BODY NEGATIVE PRESSURE; MALE; NEUROGRAPHY; PERIPHERAL CIRCULATION; PLETHYSMOGRAPHY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 3242804463     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00810.x     Document Type: Article

References (49)

1. PARFREY PS: Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 15:58-68, 2000
2. ROSTAND SG, BRUNZELL JD, CANNON RO, VICTOR RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 2:1053-1062, 1991
3. ZOCCALI C, MALLAMACI F, PARLANGO S, CUTRUPI S: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359, 2002
4. CONVERSE RL, JACOBSEN TN, TOTO RD, et al: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
5. BERNARDI D, BERNINI L, CINI G, et al: Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. Am Heart J 109:539-545, 1985
6. STEFANSKI A, SCHMIDT KG, WALDHERR R, et al: Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50:1321-1326, 1996
7. FERGUSON DW, THAMES MD, MARK AL: Effects of propranolol on reflex vascular responses to orthostatic stress in humans. Role of ventricular baroreceptors. Circulation 67:802-807, 1983
8. FOLEY RN, PARFREY PS, HARNETT JD, KENT GM: The impact of anemia on cardiomyopathy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 24:768-776, 1994
9. HALLIWELL JR, MINSON CT: Effect of hypoxia on arterial baroreflex control of heart rate and muscle sympathetic nerve activity in humans. J Appl Physiol 93:857-864, 2002
10. VALDERRÁBANO F: Anaemia management in chronic kidney disease patients: An overview of current clinical practice. Nephrol Dial Transplant 17(Suppl 1):13-18, 2002
11. MCDOUGALL IC, LEWIS NP, SAUNDERS MJ, et al: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489-493, 1990
12. GOLDBERG N, LUNDIN AP, DELANO B, et al: Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 124:424-427, 1992
13. TSAKIRIS D: Morbidity and mortality reduction associated with the use of erythropoietin. Nephron 85:2-8, 2000
14. MOCKS J: Cardiovascular mortality in hemodialysis patients treated with epoetin beta - A retrospective study. Nephron 86:455-462, 2000
15. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
16. ESCHBACH JW, ABDULHADI MH, BROWNE JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
17. RAINE AE, ROGER SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 18 (Suppl 1):76-83, 1991
18. HALLER H, CHRISTEL C, DANNENBERG L, et al: Signal transduction of erythropoietin in endothelial cells. Kidney Int 50:481-488, 1996
19. LONDON GM, ZINS B, PANNIER B: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:878-882, 1989
20. WORKING PARTY FOR EUROPEAN BEST PRACTICE GUIDELINES FOR THE MANAGEMENT OF ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE: European Best Practice Guidelines for the Management of Anemia in Patients With Chronic Renal Failure. Nephrol Dial Transplant 14:1-50, 1999
21. VALLBO AB, HAGBARTH KE, TOREBJÖRK HE, WALLIN BG: Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 59:919-957, 1979
22. DELIUS W, HAGBARTH KE, HONGELL A, WALLIN BG: Manoeuvers affecting sympathetic outflow in human muscle nerves. Acta Physiol Scand 84:82-94, 1972
23. SCHOBEL HP, OREN RM, MARK AL, FERGUSON DW: Naloxone potentiates cardiopulmonary baroreflex sympathetic control in normal humans. Circ Res 70:172-183, 1992
24. OREN RM, SCHOBEL HP, WEISS RM, et al: Importance of left atrial baroreceptors in the cardiopulmonary baroreflex of normal humans. J Appl Physiol 74:2672-2680, 1993
25. VICTOR RG, LEIMBACH WN: Effects of lower body negative pressure on sympathetic discharge to leg muscles in humans. J Appl Physiol 63:2558-2562, 1987
26. SAHN DJ, DE MARIA A, KISSLO J: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58:1072-2080, 1978
27. TROY L, POMBO J, RACKLEY C: Measurement of left ventricular wall thickness and mass by echocardiography. Circulation XLV:602-611, 1972
28. DEVEREUX RB, REICHEK N: Echocardiographic determination of left ventricular wall thickness and mass by echocardiography. Circulation 55:613-618, 1977
29. SCHMIEDER RE, MESSERLI FH, NUNEZ BD, et al: Asymmteric septal hypertrophy in arterial hypertension: Hemodynamic, endocrine and volume findings. Am J Cardiol 62:1053-1057, 1988
30. BOULOUX P, PERRET D, BESSER GM: Methodological considerations in the determination of plasma catecholamines by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 22:194-203, 1985
31. PARATI G, CASADEI R, GROPELLI AC, et al: Comparison of finger and intraarterial blood pressure monitoring at rest and during laboratory testing. Hypertension 13:647-655, 1989
32. WHITNEA RJ: The measurement of volume changes in human limbs. J Physiol 121:1-27, 1953
33. SAFAR ME, BOUTHIER JA, LEVENSON JA, SIMON AC: Peripheral large arteries and the response to antihypertensive treatment. Hypertension 5 (5 Pt 2).III63-III68, 1983
34. NORUSIS MJ: SPSS for Windows, Advanced Statistics Release 6.0, Chicago: SPSS Inc., 1993
35. FOLEY RN, PARFREY PS, HARNETT JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
36. FOLEY RN, PARFREY PS, HARNETT JD, et al: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5:2024-2031, 1995
37. VAZIRI ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33:821-828, 1999
38. LUFT FC: Erythropoietin und arterielle hypertonie. Nieren-und Hochdruckkrankheiten 28:72-76, 1999
39. LONDON GM, ZINS B, PANNIER B, et al: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:818-882, 1989
40. FOLKOW B, DI BONA GF, HJEMDAHL P, et al: Measurements of plasma norepinephrine concentrations in human primary hypertension: A word of caution on their applicability for accessing neurogenic contributions. Hypertension 5:399-403, 1983
41. CAMPESE V, KOGOSOV E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878-882, 1995
42. NG AV, CALLISTER R, JOHNSON DG, SEALS DR: Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 21:498-503, 1993
43. LIGTENBERG G, BLANKESTIJN PJ, OEY PL, et al: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321-1328, 1999
44. KLEIN IHH, LIGTENBERG G, OEY PL, et al: Enalapril and Losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14:425-430, 2003
45. RAHMAN MA, HARA K, DALY PA, et al: Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: Preliminary observations. Br Heart J 74:431-436, 1995
46. NURMINEN ML, CULMAN J, HAASS M, et al: Effects of moxonidine on blood pressure and sympathetic ton in conscious spontaneously hypertensive rats. Eur J Pharmacol 362:61-67, 1998
47. AHAMD M, BLOMQVIST CG, MULLINS CB, WILLERSON JT: Left ventricular function during lower body negative pressure. Aviat Space Environ Med 48:512-515, 1977
48. BILLMAN GE, STONE HL: Baroreceptor reflex control of heart rate: A predictor of sudden cardiac death. Circulation 66:874-880, 1982
49. TYLER HR: Uraemic neuritis and the autonomic nervous system. N Engl J Med 290:685-686, 1974